Emerging Novel ADC Webinar
This webinar provides an in-depth analysis of the most promising developments in novel drug conjugates, including the exploration of diverse payloads and targets that are pushing the boundaries of precision medicine. Examine the rise of Bispecific ADCs (BsADCs) and antibody degrader conjugates, which offer new mechanisms of action and improved specificity, paving the way for safer and more effective therapies.
Our Experts
Yu-Shin Hsu
House Speaker
Cell Therapy Lead Research Analyst
Beacon
Callum Angus
House Speaker
Senior Market Analyst
Hanson Wade Intelligence
Jake Morris
Moderator
Senior Account Manager
Beacon
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
